ZyVersa progresses with novel inflammation treatment

WESTON, Fla. - ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a micro-cap biopharmaceutical company with a market capitalization of $1.82 million specializing in the development of treatments for renal and inflammatory diseases, has outlined the current status and future milestones of its Inflammasome ASC Inhibitor IC 100. According to InvestingPro data, the company’s stock has experienced significant volatility, declining over 88% in the past year. The company’s CEO, Stephen C. Glover, provided an update on the drug’s development, which is focused on chronic inflammatory diseases, with an initial emphasis on obesity-associated cardiometabolic conditions.

Inflammasome inhibitors have garnered attention due to their potential role in a wide array of diseases. ZyVersa’s IC 100 is unique in its approach by targeting ASC to mitigate both the onset and spread of inflammation, which could result in improved disease control compared to inhibitors that target a single inflammasome type.

The company is preparing to initiate a proof-of-concept study with IC 100 in a diet-induced obesity mouse model within the first half of 2025. Preliminary results are expected in the second half of the same year. Additionally, ZyVersa plans to submit an Investigational New Drug Application for IC 100 in the second half of 2025, followed by a Phase 1 clinical trial in overweight individuals with cardiometabolic risk factors.

ZyVersa has completed a preclinical study funded by The Michael J. Fox Foundation on the potential of IC 100 to treat Parkinson’s disease, with results pending publication. A second grant request for a proof-of-concept preclinical study in a Parkinson’s disease animal model has been submitted to the foundation, with a response anticipated in June 2025.

The company’s announcement comes at a time when the global drug market for anti-inflammatory biologics, valued at $105 billion in 2024, is projected to reach $186 billion by 2034, according to Precedence Research. InvestingPro analysis indicates the company faces financial challenges with a current ratio of 0.15, suggesting potential liquidity concerns. Investors should note that ZyVersa’s next earnings report is scheduled for May 12, 2025. The growth is attributed to an increase in chronic inflammatory diseases driven by aging populations, lifestyle changes, and environmental factors.

ZyVersa’s development of IC 100 aims to capitalize on this expanding market by addressing the unmet medical needs within the realm of inflammatory and renal diseases. The information provided is based on a press release statement by ZyVersa Therapeutics. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics that could help evaluate the company’s potential in this expanding market.

In other recent news, ZyVersa Therapeutics has shared significant updates regarding its drug development efforts and corporate activities. The company is advancing its Phase 2a trial for VAR 200, targeting Diabetic Kidney Disease, with the aim of gathering vital data to inform further trials for Focal Segmental Glomerulosclerosis (FSGS). ZyVersa has also announced a new financing agreement with a U.S. institutional investor, expected to raise approximately $2 million to support its working capital needs. Meanwhile, the company has appointed CBIZ CPAs P.C. as its new accounting firm following the acquisition of its former auditor Marcum LLP’s attest business.

In a promising development, ZyVersa’s Inflammasome ASC Inhibitor IC 100 has shown potential in treating obesity-associated cardiomyopathy and Alzheimer’s disease, as evidenced by recent studies published in reputable journals. The studies highlight IC 100’s ability to reduce inflammation and improve metabolic activity in disease models. CEO Stephen C. Glover emphasized the potential of IC 100 in addressing high unmet medical needs in both cardiovascular and neurodegenerative diseases. These advancements reflect ZyVersa’s strategic focus on leveraging its proprietary technologies to develop treatments for inflammatory and kidney diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.